Active, Not Recruiting
A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma - CC-90010-GBM-002
Updated:
2 May, 2023
|
ClinicalTrials.gov
Phase
Gender(s)
Age Range
Active, Not Recruiting
Inclusion Criteria: - Primary isocitrate dehydrogenase (IDH)-wild type newly diagnosed World Health Organization (WHO) Grade IV Glioblastoma - O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status must be available prior to randomization - Karnofsky performance status of ≥70 Exclusion Criteria: - Indeterminate MGMT promoter methylation status - Biopsy only of glioblastoma (GBM) at surgery, defined as < 20% resection of enhancing tumor - Any known metastatic extracranial or leptomeningeal disease Other protocol-defined inclusion/exclusion criteria apply
If you want to report a side effect, you can report directly to the Danish Medicines Agency via the website www.meldenbivirkning.dk
We recommend that you also contact BMS to report side effects.
Side effects and other reportable events are defined here
Report side effects or product quality complaints: Medical Information
466-DK-2200001